Kenvue Inc. (NYSE:KVUE) Stock Holdings Decreased by Sentry Investment Management LLC

Sentry Investment Management LLC lowered its stake in Kenvue Inc. (NYSE:KVUE) by 9.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 9,042 shares of the company’s stock after selling 971 shares during the period. Sentry Investment Management LLC’s holdings in Kenvue were worth $195,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of KVUE. Citigroup Inc. bought a new stake in shares of Kenvue in the 2nd quarter worth about $57,000. Osaic Holdings Inc. bought a new stake in shares of Kenvue in the 2nd quarter worth about $144,000. Northern Trust Corp bought a new stake in shares of Kenvue in the 2nd quarter worth about $1,244,000. PNC Financial Services Group Inc. acquired a new position in shares of Kenvue in the 2nd quarter valued at about $73,000. Finally, BlackRock Inc. acquired a new position in shares of Kenvue in the 2nd quarter valued at about $164,895,000. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

KVUE has been the subject of several research reports. Royal Bank of Canada decreased their price target on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. William Blair initiated coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating for the company. UBS Group lifted their price target on shares of Kenvue from $20.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, December 19th. The Goldman Sachs Group initiated coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target for the company. Finally, JPMorgan Chase & Co. decreased their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $24.85.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $19.11 on Wednesday. The company has a 50 day moving average of $19.85 and a 200-day moving average of $20.17. Kenvue Inc. has a twelve month low of $17.82 and a twelve month high of $27.80. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. Kenvue’s quarterly revenue was down 2.7% on a year-over-year basis. On average, research analysts expect that Kenvue Inc. will post 1.17 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.19%. The ex-dividend date was Tuesday, February 13th.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.